Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Companyâs lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Employees

Sector

Biotechnology & Medical Research

Calendar

15/01 - J.P. Morgan Healthcare Conference

More about the company

Quotes

Date	Price	Change	Volume
12/26/12	5.770 $	-0.69%	9,90,785
09/26/09	5.810 $	+0.87%	11,39,974
08/26/08	5.760 $	-0.17%	11,12,338
07/26/07	5.770 $	+4.15%	14,45,077
06/26/06	5.540 $	-4.48%	20,72,475

Delayed Quote Nasdaq, January 13, 2026 at 02:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.770USD

Average target price

10.81USD

Spread / Average Target

+87.39%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 13/01/2026 am IST			5-day change	1st Jan Change
5.770 ^USD	-0.69%		-0.52%	-4.31%

09/01	Savara, PANTHERx Enter Exclusive Distribution Agreement for MOLBREEVI	MT
09/01	Savara Inc. Announces an Exclusive Distribution Agreement for MOLBREEVI	CI

Capitalization	139.24Cr 119.23Cr 110.88Cr 103.38Cr 193.16Cr 13TCr 207.18Cr 1.28TCr 502.09Cr 6TCr 522.19Cr 511.48Cr 22TCr	P/E ratio 2025 *	-11.2x	P/E ratio 2026 *	-14.1x
Enterprise value	139.24Cr 119.23Cr 110.88Cr 103.38Cr 193.16Cr 13TCr 207.18Cr 1.28TCr 502.09Cr 6TCr 522.19Cr 511.48Cr 22TCr	EV / Sales 2025 *	-	EV / Sales 2026 *	99.4x
Free-Float	95.41%	Yield 2025 *	-	Yield 2026 *	-

09/01	Savara, PANTHERx Enter Exclusive Distribution Agreement for MOLBREEVI	MT
09/01	Savara Inc. Announces an Exclusive Distribution Agreement for MOLBREEVI	CI
22/12	Savara Resubmits Molbreevi Application to FDA for Rare Lung Disease	MT
22/12	Savara resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi	RE
22/12	Savara Inc. Resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis	CI
22/12	Savara Inc.(NasdaqGS:SVRA) added to S&P Biotechnology Select Industry Index	CI
11/12	Savara Inc. Announces European Patent Office Intends to Grant A Patent for the Liquid Formulation of MOLBREEVI	CI
11/12	Savara to Get Patent for Liquid Formulation of Lung Disease Therapy from European Patent Office	MT
09/12	Certain Restricted Stock Units of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
09/12	Certain Options of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
09/12	Certain Warrants of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
09/12	Certain Pre-Funded Warrants of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI
09/12	172,836,922 Common Stock of Savara Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025.	CI

14/11	Oppenheimer Adjusts Price Target on Savara to $9 From $8, Maintains Outperform Rating	MT
08/25/08	Oppenheimer Adjusts Savara Price Target to $8 From $6, Maintains Outperform Rating	MT
16/25/16	Savara Shares Rise After Upgrade From HC Wainwright	MT
15/25/15	HC Wainwright Upgrades Savara to Buy From Neutral, $5 Price Target	MT
15/25/15	Oppenheimer Adjusts Price Target on Savara to $6 From $5, Maintains Outperform Rating	MT

Savara Inc. Share Price

Equities

SVRA

US8051111016

Biotechnology & Medical Research

Valuation: Savara Inc.

Chart: Savara Inc.

Latest news: Savara Inc.

Last Transcript: Savara Inc.

Analysts' recommendations: Savara Inc.

Press Releases: Savara Inc.

News in other languages: Savara Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Savara Inc.

ETFs: Savara Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

09/01	Savara : Corporate Presentation	PU
09/01	PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*	BU
22/12	Savara : Corporate Presentation	PU
22/12	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)	BU
17/12	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference	BU

28/21/28	Relief Therapeutics se dote d'un responsable des opérations
28/21/28	Relief Therapeutics ernennt Taneli Jouhikainen zum Chief Operating Officer
28/21/28	EQS-News : Relief ernennt Dr. Taneli Jouhikainen zum Chief Operating Officer

1 day	-0.69%
1 week	-0.52%
Current month	-4.31%
1 month	-16.62%
3 months	+71.22%
6 months	+141.42%
Current year	-4.31%

1 week	5.52	5.96
1 month	5.47	6.91
Current year	5.47	6.03
1 year	1.89	7
3 years	1.63	7
5 years	1.02	7
10 years	0.69	17.19

Manager	Title	Age	Since
Matthew Pauls CEO	Chief Executive Officer	55	01/12/2020
David Lowrance DFI	Director of Finance/CFO	58	01/11/2016
Yasmine Wasfi CTO	Chief Tech/Sci/R&D Officer	-	01/12/2023

Director	Title	Age	Since
Nevan Elam BRD	Director/Board Member	58	01/02/2009
Richard Hawkins BRD	Director/Board Member	77	01/10/2010
Joseph McCracken BRD	Director/Board Member	71	01/10/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SAVARA INC.	-0.69%	-0.52%	+107.55%	+220.56%	140.21Cr
ARGENX SE	-3.14%	-1.73%	+3.87%	+82.75%	4.94TCr
WUXI APPTEC CO., LTD.	-0.40%	+4.35%	+84.93%	+8.53%	4.21TCr
INSMED INCORPORATED	-4.69%	-4.27%	+157.04%	+768.57%	3.75TCr
BIONTECH SE	+2.33%	+5.50%	-16.83%	-31.61%	2.51TCr
GENMAB A/S	-0.92%	+7.56%	+38.32%	-21.04%	2.09TCr
WUXI BIOLOGICS (CAYMAN) INC.	+4.10%	+16.47%	+131.01%	-42.80%	1.96TCr
SUMMIT THERAPEUTICS INC.	-13.41%	-2.29%	-4.54%	+323.88%	1.52TCr
AKESO, INC.	-2.22%	+4.70%	+121.30%	+166.81%	1.51TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.82%	+12.41%	+188.53%	-	1.43TCr
Average	-0.76%	+5.34%	+81.12%	+163.96%	2.41TCr
Weighted average by Cap.	-1.36%	+3.65%	+71.55%	+172.14%

	2025 *	2026 *
Net sales	-	1.4Cr 1.2Cr 1.12Cr 1.04Cr 1.94Cr 126.26Cr 2.08Cr 13Cr 5.05Cr 60Cr 5.25Cr 5.15Cr 221.47Cr
Net income	-11Cr -9.8Cr -9.11Cr -8.49Cr -16Cr -1.03TCr -17Cr -104.95Cr -41Cr -493.28Cr -43Cr -42Cr -1.81TCr	-9.39Cr -8.04Cr -7.48Cr -6.97Cr -13Cr -846.26Cr -14Cr -86Cr -34Cr -404.85Cr -35Cr -34Cr -1.48TCr
Net Debt	-	-